Frazier Life Sciences Management L.P. Has $613.03 Million Stake in NewAmsterdam Pharma Company N.V. $NAMS

Key Points

• Frazier Life Sciences Management increased its NewAmsterdam Pharma stake by 6.8% to 18.09 million shares, valued at approximately $613 million and representing about 15.13% of the company. Institutional investors collectively own 89.89% of NAMS.
• NewAmsterdam Pharma reported a quarterly loss of $0.52 per share, slightly worse than the $0.48 analyst consensus, while revenue of $3.70 million exceeded expectations. Analysts maintain a “Moderate Buy” consensus with an average price target of $49.73.
• NAMS opened at $25.40, well below its 52-week high of $42.21. Meanwhile, insiders sold 270,000 shares worth approximately $7.76 million over the past 90 days.

Frazier Life Sciences Management L.P. lifted its stake in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 6.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 18,088,902 shares of the company's stock after purchasing an additional 1,145,128 shares during the quarter. NewAmsterdam Pharma comprises 13.3% of Frazier Life Sciences Management L.P.'s portfolio, making the stock its 2nd largest position. Frazier Life Sciences Management L.P. owned approximately 15.13% of NewAmsterdam Pharma worth $613,033,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in NAMS. Farther Finance Advisors LLC increased its position in NewAmsterdam Pharma by 4,425.0% in the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company's stock worth $25,000 after buying an additional 708 shares during the period. Wells Fargo & Company MN boosted its stake in NewAmsterdam Pharma by 50.0% during the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company's stock valued at $32,000 after purchasing an additional 300 shares during the period. KBC Group NV acquired a new position in NewAmsterdam Pharma during the 1st quarter valued at about $37,000. Navalign LLC bought a new position in NewAmsterdam Pharma in the 4th quarter worth about $46,000. Finally, Empowered Funds LLC bought a new position in NewAmsterdam Pharma in the 4th quarter worth about $85,000. Institutional investors own 89.89% of the company's stock.

NewAmsterdam Pharma Stock Performance

NAMS stock opened at $25.40 on Monday. NewAmsterdam Pharma Company N.V. has a one year low of $23.05 and a one year high of $42.21. The firm has a 50-day moving average of $29.68 and a two-hundred day moving average of $31.60. The firm has a market capitalization of $3.04 billion, a PE ratio of -11.76 and a beta of 0.09.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative return on equity of 34.81% and a negative net margin of 3,644.21%.The firm had revenue of $3.70 million during the quarter, compared to analysts' expectations of $2.83 million. On average, equities research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.82 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on NAMS. Jefferies Financial Group reaffirmed a "buy" rating and set a $45.00 price target on shares of NewAmsterdam Pharma in a report on Monday, July 20th. Weiss Ratings reiterated a "sell (d-)" rating on shares of NewAmsterdam Pharma in a research note on Friday, July 17th. BMO Capital Markets assumed coverage on NewAmsterdam Pharma in a report on Monday, July 20th. They set an "outperform" rating and a $58.00 target price on the stock. Finally, Royal Bank Of Canada decreased their price target on shares of NewAmsterdam Pharma from $51.00 to $50.00 and set an "outperform" rating on the stock in a research report on Thursday, August 6th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $49.73.

Insiders Place Their Bets

In other news, insider Johannes Kastelein sold 125,000 shares of NewAmsterdam Pharma stock in a transaction on Monday, August 24th. The stock was sold at an average price of $26.91, for a total transaction of $3,363,750.00. Following the transaction, the insider owned 69,302 shares in the company, valued at approximately $1,864,916.82. The trade was a 64.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Louise Kooij sold 105,000 shares of the company's stock in a transaction on Monday, July 20th. The shares were sold at an average price of $30.34, for a total value of $3,185,700.00. Following the transaction, the chief accounting officer directly owned 24,353 shares in the company, valued at $738,870.02. The trade was a 81.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 270,000 shares of company stock valued at $7,757,450 in the last 90 days. Corporate insiders own 12.74% of the company's stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.

Want to see what other hedge funds are holding NAMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source